Introduction
received tapered daily intravenous methylprednisone at a dose of 1000 mg, 500 mg and 100 mg sequentially. Renal transplant recipients with chronic HBV infection Isoniazid prophylaxis (300 mg daily) was given because may have progression of HBV associated liver disease of a history of inguinal tuberculous lymphadenitis following transplantation. diagnosed and treated 6 years previously with 12 This progressive hepatitis may take a number of months of supervised combination therapy. forms. The most fulminant form appears to be that of Eight weeks after transplantation the patient was fibrosing cholestatic hepatitis (FCH ). FCH is a unique admitted with deteriorating renal function. She was and often rapidly fatal form of progressive liver disease treated initially for rejection with two daily boluses of due to HBV that occurs only in the immunosuppressed intravenous methylprednisone (1000 mg). Graft biopsy patient. Initially described in liver transplant recipients and blood cyclosporin levels suggested cyclosporin with recurrence of HBV [1], FCH has now been toxicity and her graft function improved after reducdescribed as a rare complication of renal transplanta-tion of her cyclosporin dose to 6 mg/kg/day. Liver tion [2] [3] [4] . function tests at that time suggested mild cholestasis This rare complication of HBV following trans- ( Table 1) . plantation highlights the risks of renal transplantation Sixteen weeks after transplantation the graft function in patients with active HBV disease, which may well again deteriorated. The patient was now clinically be a contraindication to transplantation. HBsAg-jaundiced with biochemistry suggesting progressive positive patients require careful assessment before cholestasis ( Table 1) . Abdominal ultrasonography transplantation, with close monitoring for the emer-revealed normal architecture of the liver and biliary gence of progressive HBV infection should transplanta-tree. Both isoniazid and azathioprine were stopped tion be performed. without benefit. Serological tests for hepatitis A (IgM, IgG), hepatitis C, and hepatitis D were negative, however a viral culture of plasma with immunofluo-
Case report
rescence revealed CMV viraemia. She received a 3-week course of intravenous ganciclovir with documented A 37-year-old woman with end-stage renal failure due clearance of CMV viraemia but without discernible to chronic glomerulonephritis underwent cadaveric effect on her progressive cholestatic hepatitis. renal transplantation in September 1995. She had been Over a 6-week period the patient deteriorated clinicon haemodialysis for a period of 13 years. Prior to ally, with progressive cholestasis and the development transplantation she had positive serology for HBsAg, of hepatocellular failure. Her biliary anatomy was hepatitis B 'e' antigen (HBeAg) and hepatitis B 'e' further defined with endoscopic retrograde cholangiantibody (HBeAb). At the time of transplantation her opancreatography (ERCP), which revealed normal serum bilirubin and liver transaminase levels were anatomy of both intrahepatic and extrahepatic ducts. normal and she had undetectable levels of HBV DNA. At this stage repeat serology for HBV revealed a Both the recipient and donor were seropositive for substantially elevated titre of HBV DNA (800 fmol/l ). The patient died three days after liver biopsy with progression following transplantation. Liver biochemistry and HBVDNA levels should be closely followed advanced liver failure. Permission for postmortem examination was refused.
in these patients, with a low threshold for performance of a liver biopsy should there be a significant change Histological examination of the liver biopsy revealed micronodular cirrhosis, ductular cholestasis and bal-in either of these parameters.
Various treatment options for progressive HBV looning degeneration of hepatocytes with ground-glass intracytoplasmic inclusions. Minimal inflammation infection in the immunosuppressed patient have arisen from the experience of liver transplantation. Prowas present. Immunoperoxidase staining was strongly positive within hepatocytes for HBsAg and hepatitis B phylactic infusions of HBV immunoglobulin as well as treatment with lamivudine appear to reduce disease core antigen (HBcAg), but negative for CMV. The biopsy findings were consistent with previous reports activity [9] . Ganciclovir therapy has also been reported to reduce titres of HBVDNA [10] with one isolated of fibrosing cholestatic hepatitis.
case of prolonged survival in a case of FCH occurring in a liver-allograft recipient maintained on long-term Discussion ganciclovir [6 ] .
Renal-transplant recipients with HBV reactivation differ from their liver-transplant counterparts. The life FCH is a rapidly progressive form of hepatitis B of liver-transplant recipients is critically dependent on infection that occurs only in the presence of significant function of the transplanted organ and thus the immunosuppression. Its development imparts a poor immunosuppression necessary to prevent rejection. In prognosis, with death occurring in the first year followrenal transplantation dialysis is an alternative method ing its development in the majority of patients [5, 6 ] .
of replacing function of the transplant organ; therefore The fact that it is a recently recognized condition may withdrawal of immunosuppression and loss of the graft be a reflection of changes in the type and degree of is still compatible with life. Sudden cessation of immunosuppressive therapy now employed to prevent immunosuppression in the setting of chronic viral rejection. It has a different pathogenesis from chronic hepatitis can result in acute liver decompensation conhepatitis in the immunocompetent patient, with hepatic sistent with a sudden increase in immune activity injury probably mediated through the accumulation of against large amounts of HBV. We are unaware of large amounts of HBV particles [5] . This is in contrast any reports of the effect of gradual reduction of to chronic hepatitis in normal individuals, in whom immunosuppression, and it is possible that such reduchepatic injury is the result of immune activity. This tion combined with antiviral therapy may allow the difference may account for the unusual clinical features disease to regress to a less aggressive form. of FCH, in particular the prominence of cholestasis.
In conclusion this case of rapidly fatal HBV infection The possibility of fatal HBV disease after renal following renal transplantation illustrates the need for transplantation necessitates a clear approach to the a comprehensive approach toward HBsAg carriers prevention and screening of HBV disease in the dialysis both prior to and following transplantation, and population. Vaccination of dialysis patients is routine strengthens the argument for routine HBV vaccination in many centres, and in association with isolation of of all dialysis patients. HBV carriers and reduced exposure to blood products has had a noticeable impact on the number of dialysis patients acquiring HBV [7] . Patients who are carriers 
